Literature DB >> 3159522

Prevention of immune precipitation by purified components of the alternative pathway.

J K Naama, E Holme, E Hamilton, K Whaley.   

Abstract

The role of the alternative pathway in complement-mediated prevention of immune precipitation has been investigated by the use of BSA-anti-BSA immune complex (IC) purified components. For immune precipitation to be prevented all six alternative pathway components (C3, factors B D, P, H and I) were required. In the absence of one or both of the control proteins H and I, excessive fluid phase turnover of C3 occurred with precipitation of IC. Kinetic studies showed that in the presence of the control proteins, an initial phase of precipitation occurred, and was followed by a phase of resolubilization of IC. When the efficiency of classical and alternative pathways in the prevention of immune precipitation was compared it was found that the classical pathway proteins were more effective than the alternative pathway components. A reaction mixture containing the components of both pathways was no better than the classical pathway protein alone. 125I-C3 was bound to IC which had been rendered soluble in the presence of classical or alternative pathway components. A molar ratio of two molecules C3b:five molecules IgG was calculated. Other complement components which were bound to IC which had been formed in the presence of serum were C1q, C4, C2, C3, C5, P and H. Factors B and I were not detected. Our findings suggest that the alternative pathway is of secondary importance to the classical pathway in the prevention of immune precipitation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3159522      PMCID: PMC1576996     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  The unactivated form of the first component of human complement, C1.

Authors:  I Gigli; R R Porter; R B Sim
Journal:  Biochem J       Date:  1976-09-01       Impact factor: 3.857

2.  Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3).

Authors:  L G Hunsicker; S Ruddy; K F Austen
Journal:  J Immunol       Date:  1973-01       Impact factor: 5.422

3.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

4.  Prevention of immune precipitation by purified classical pathway complement components.

Authors:  J K Naama; A O Hamilton; A C Yeung-Laiwah; K Whaley
Journal:  Clin Exp Immunol       Date:  1984-11       Impact factor: 4.330

5.  The reaction mechanism of human C5 in immune hemolysis.

Authors:  N R Cooper; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1970-10-01       Impact factor: 14.307

6.  Third component of human complement: purification from plasma and physicochemical characterization.

Authors:  B D Tack; J W Prahl
Journal:  Biochemistry       Date:  1976-10-05       Impact factor: 3.162

7.  Requirements for the solubilization of immune aggregates by complement: assembly of a factor B-dependent C3-convertase on the immune complexes.

Authors:  M Takahashi; B F Tack; V Nussenzweig
Journal:  J Exp Med       Date:  1977-01-01       Impact factor: 14.307

8.  Modulation of the alternative complement pathways by beta 1 H globulin.

Authors:  K Whaley; S Ruddy
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307

9.  Properdin factor D: characterization of its active site and isolation of the precursor form.

Authors:  D T Fearon; K F Austen; S Ruddy
Journal:  J Exp Med       Date:  1974-02-01       Impact factor: 14.307

10.  Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.

Authors:  D T Fearon; K F Austen
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

View more
  10 in total

1.  Mechanism of action of an inhibitor of complement-mediated prevention of immune precipitation.

Authors:  A E Ahmed; J Veitch; K Whaley
Journal:  Immunology       Date:  1990-06       Impact factor: 7.397

2.  Guinea pigs with inherited deficiencies of complement components C2 or C4 have characteristics of immune complex disease.

Authors:  E C Böttger; T Hoffmann; U Hadding; D Bitter-Suermann
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

3.  BSA-anti-BSA immune complexes formed in the presence of human complement do not bind to autologous red blood cells.

Authors:  L Varga; E Thiry; G Füst
Journal:  Immunology       Date:  1988-07       Impact factor: 7.397

4.  Clearance kinetics and organ uptake of complement-solubilized immune complexes in mice.

Authors:  M T Aguado; M Mannik
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

5.  An inhibitor of complement-mediated prevention of immune precipitation in rheumatoid arthritis--relationship to disease activity and systemic manifestations.

Authors:  W S Mitchell; J Veitch; J Hunter; A Zoma; H Capell; K Whaley
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

6.  Purification of a plasma protein that inhibits complement-mediated prevention of immune precipitation.

Authors:  A E Ahmed; K Whaley
Journal:  Immunology       Date:  1988-05       Impact factor: 7.397

7.  The plasma protein which inhibits complement-mediated prevention of immune precipitation is an Fc binding protein.

Authors:  A E Ahmed; P Bird; I C McKay; K Whaley
Journal:  Immunology       Date:  1989-01       Impact factor: 7.397

8.  Recombinant soluble Fc gamma RII inhibits immune complex precipitation.

Authors:  A L Gavin; B D Wines; M S Powell; P M Hogarth
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

9.  Circulating immune complexes associated with decreased complement-mediated inhibition of immune precipitation in sera from patients with bacterial endocarditis.

Authors:  M A Kerr; E Wilton; J K Naama; K Whaley
Journal:  Clin Exp Immunol       Date:  1986-02       Impact factor: 4.330

10.  Innate immunity during Equid herpesvirus 1 (EHV-1) infection.

Authors:  C G Bridges; N Edington
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.